CTSL and prostate cancer: Burton et al. recently demonstrated in mesenchymal prostate cancer cells that this effect could be abrogated via inhibition of cathepsin L. Cathepsin L contains both full and half-site AREs, both intronic and upstream of its transcriptional start site and its expression could not be detected in the androgen-independent cell line.